Evogene (EVGN) Long-Term Investments (2013 - 2026)
Evogene (EVGN) posted Long-Term Investments of $570000.0 for Q1 2026, up 1225.58% sequentially from $43000.0 in Q4 2025, and up 612.5% YoY from $80000.0 in Q1 2025.
Evogene (EVGN) Long-Term Investments (2013 - 2026) Analysis & Trends
Evogene has reported Long-Term Investments for 6 years, with the latest figure at $570000.0 in Q1 2026.
- Quarterly Long-Term Investments rose 612.5% year-over-year to $570000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $570000.0 (up 612.5% YoY) and the FY2025 annual result came in at $43000.0, down 47.56% from the prior year.
- Long-Term Investments improved to $570000.0 in Q1 2026 per EVGN's latest filing, from $43000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $570000.0 in Q1 2026 and troughed at $15000.0 in Q2 2025.
- A 3-year average of $139750.0 and a median of $88500.0 in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments slumped 85.0% in 2025, then soared 612.5% in 2026.
- Over 3 years, Long-Term Investments stood at $82000.0 in 2024, then sank by 47.56% to $43000.0 in 2025, then soared by 1225.58% to $570000.0 in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $570000.0, $43000.0, and $15000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 570,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 570,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 82,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Mar 31, 2015 | 382,000.00 |
| Dec 31, 2014 | 382,000.00 |
| Sep 30, 2014 | 471,000.00 |
| Jun 30, 2014 | 471,000.00 |
| Mar 31, 2014 | 471,000.00 |
| Dec 31, 2013 | 471,000.00 |
| Sep 30, 2013 | 365,000.00 |
| Jun 30, 2013 | 365,000.00 |
| Mar 31, 2013 | 365,000.00 |